Arm Holdings (ARM 6.06%) has emerged as a top AI stock following its initial public offering in September 2023. The chip design company, which specializes in power-efficient CPU architecture, seemed to be initially misunderstood by investors, but the stock has since tripled from its IPO price.

FAIRPORT, N.Y.--(BUSINESS WIRE)--Monro, Inc. (Nasdaq: MNRO), a leading provider of automotive undercar repair and tire services, today announced that its Board of Directors has declared a quarterly cash dividend of $.28 per share on the Company's outstanding shares of common stock, including the shares of common stock to which the holders of the Company's Class C Convertible Preferred Stock are entitled. The dividend is payable on March 11, 2025 to shareholders at the close of business on Febru.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/caribou-biosciences-inc-lawsuit-submission-form?prid=129489&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your ModivCare Inc. (NASDAQ:MODV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/modivcare-inc-lawsuit-submission-form?prid=129490&wire=1 or contact Joseph E. Levi, Esq.

Douglas Elliman's CEO Howard Lorber has retired, replaced by Michael Liebowitz, who appears to be focused on cost-cutting and restructuring the executive team. Despite cost-cutting efforts, I do not foresee Douglas Elliman returning to profitability in 2025 without a concrete plan for revenue diversification. The real estate market remains challenging with high mortgage rates and low affordability, impacting transaction volumes and the company's financial outlook.

Novartis' robust drug pipeline and strong financials, including an AA- credit rating, support an 11% annual return expectation by 2027. The company's diverse blockbuster portfolio and strategic cost management drove a 15.1% sales increase and 29% EPS growth in Q4 2024. Novartis' shares are undervalued by 11%, offering a 33% cumulative return potential through 2027, with a secure and growing 3.5% dividend yield.

Thank you to the Seeking Alpha community for your support! Reaching 40,000 followers is a dream come true. Your feedback fuels my work. I've invested 91% of my net worth in 23 high-conviction dividend stocks. Focused on wide-moat businesses, I prioritize quality and long-term growth over yield. My portfolio has outperformed the S&P 500, and I'm confident in its future. I expect a rotation to value stocks, and I'll keep sharing insights to grow together.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Transocean Ltd. (NYSE:RIG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transocean-ltd-lawsuit-submission-form?prid=129474&wire=1 or contact Joseph E.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Micron Technology, Inc. (NASDAQ:MU) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/micron-technology-inc-lawsuit-submission-form?prid=129481&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your MGP Ingredients, Inc. (NASDAQ:MGPI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/mgp-ingredients-inc-lawsuit-submission-form?prid=129488&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Nextracker Inc. (NASDAQ:NXT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/nextracker-inc-lawsuit-submission-form?prid=129464&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Innovative Industrial Properties, Inc. (NYSE:IIPR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/innovative-industrial-properties-inc-lawsuit-submission-form?prid=129465&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your TELUS International (Cda) Inc. (NYSE:TIXT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/telus-international-lawsuit-submission-form?prid=129466&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Elastic N.V. (NYSE:ESTC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/elastic-n-v-lawsuit-submission-form?prid=129469&wire=1 or contact Joseph E.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Crocs, Inc. (NASDAQ:CROX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/crocs-inc-lawsuit-submission-form?prid=129470&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=129471&wire=1 or contact Joseph E. Levi, Esq.

The Company Is on Track to Complete the Interim Data Analysis Before the End of Q1 2025 and to Submit the Findings to the U.S. Food and Drug Administration (FDA) Philadelphia, Pennsylvania--(Newsfile Corp. - February 14, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003), which is currently underway in nine (9) clinical sites in United States, has now randomized more than 50% of the 60 patients expected to be enrolled in the study.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Capri Holdings Limited (NYSE:CPRI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/capri-holdings-lawsuit-submission-form?prid=129467&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your Joint Stock Company Kaspi.kz (NASDAQ:KSPI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/joint-stock-company-kaspi-kz-lawsuit-submission-form?prid=129468&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Constellation Brands, Inc. ("Constellation Brands, Inc.") (NYSE:STZ) concerning possible violations of federal securities laws. On January 10, 2025, Constellation issued a press release announcing the company's third quarter fiscal year 2025 results, showcasing a significant miss on sales performance in the Beer segment and an even steeper miss for the Wine & Spirits segment.